1386 related articles for article (PubMed ID: 8603815)
1. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice.
Fujii H; Inobe M; Kimura F; Murata J; Murakami M; Onishi Y; Azuma I; Uede T; Saiki I
Int J Cancer; 1996 Apr; 66(2):219-24. PubMed ID: 8603815
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with B7-1+ tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect.
Fujii H; Inobe M; Hayakawa Y; Kimura F; Murakami M; Onishi Y; Azuma I; Uede T; Saiki I
Clin Exp Metastasis; 1998 Feb; 16(2):141-8. PubMed ID: 9514095
[TBL] [Abstract][Full Text] [Related]
3. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
4. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.
Cho D; Kim TG; Lee W; Hwang YI; Cho HI; Han H; Kwon O; Kim D; Park H; Houh D
J Invest Dermatol; 2000 May; 114(5):928-34. PubMed ID: 10771473
[TBL] [Abstract][Full Text] [Related]
6. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
7. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
10. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
[TBL] [Abstract][Full Text] [Related]
13. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
14. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
15. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity.
Chong H; Hutchinson G; Hart IR; Vile RG
Hum Gene Ther; 1996 Sep; 7(14):1771-9. PubMed ID: 8886848
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
17. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
18. [Abrogated or decreased tumorigenicity and metastasis induced by retroviral-mediated B7.1 gene transfer on murine tumors with different immunogenicity].
Ma Q; Wu Y; Yu L
Zhonghua Yi Xue Za Zhi; 1997 May; 77(5):374-7. PubMed ID: 9772496
[TBL] [Abstract][Full Text] [Related]
19. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G
Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B7-1 gene transfection.
Sakate Y; Yashiro M; Tanaka H; Sunami T; Kosaka K; Hirakawa K
J Surg Res; 2004 Nov; 122(1):89-95. PubMed ID: 15522320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
